StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$40.59+2.14 (+5.57%)

Close on Nov 18, 2026Market cap $41.28MP/E –Yield –

IRulya Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

IRulya Therapeutics's price to book ratio was 20.6× on Jul 31, 2026, against 42.3× a year earlier. Over the last 5 years it ranged from 4.4× to 402.0×, with a median of 18.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 202620.6×−130.2
2025Oct 31, 2025150.8×+114.8
2024Dec 31, 202436.0×+26.8
2023Dec 29, 20239.2×+4.8
2022Dec 30, 20224.4×−52.4
2021Dec 31, 202156.8×−30.3
2020Dec 31, 202087.2×−149.6
2019Dec 31, 2019236.8×–

More IRulya Therapeutics figures

See a number that looks wrong?